Sana’s Cell Therapy Restores Insulin Without Immunosuppression: A Game Changer for Type 1 Diabetes

Published on Spencer Knight via LinkedIn

Sana Biotechnology has announced successful first-in-human results using HIP-engineered islet cells that restored insulin production in a Type 1 diabetes patient—without the need for immunosuppressive drugs. The cells produced insulin in response to meals, evaded immune attack, and maintained graft survival for at least 28 days post-transplant. Spencer Knight calls this a true breakthrough: it addresses both the immune barrier and scalability challenges that have long limited cell-based diabetes treatments.

Read the full post on LinkedIn:

👉 Spencer Knight: “Breakthrough in Cell Therapy: Allogeneic Cure for Type 1 Diabetes”

Images used are for illustrative purposes only and do not depict actual persons, products, or facilities. For full details, please refer to the original article via the provided link.